{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-030129","form_type":"8-K","ticker":"INMB","cik":"0001711754","company_name":"Inmune Bio, Inc.","filed_at":"2025-04-09T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.429323+00:00","generated_at":"2026-05-23T18:25:14.491989+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"INmune Bio presents MINDFul Phase 2 baseline data; top-line results expected June 2025","bullets":["Poster at AD/PD conference details demographics: mean age 72.5 years, 69.2% APOE ε4 carriers.","64.9% of enrolled patients positive for >1 biomarker of immune dysfunction (hsCRP, ESR, HbA1C, APOE ε4).","Trial enrolled patients with MCI or mild AD; EMACC composite used as primary cognitive endpoint.","Screen failures driven mainly by MMSE inclusion criteria; enrollment completed November 2024.","Top-line results from the 24-week, randomized, placebo-controlled study expected in June 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-030129","json":"https://secwatch.observer/filing/0001213900-25-030129.json","markdown":"https://secwatch.observer/filing/0001213900-25-030129.md","text":"https://secwatch.observer/filing/0001213900-25-030129.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1711754/000121390025030129/0001213900-25-030129-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1711754/000121390025030129/ea0237701-8k_inmune.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T18:25:14.491989+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}